51785-82-1

Usage

Uses

Used in Pharmaceutical Development:
BOC-PRO-GLY-OH is used as a building block for the synthesis of complex peptides, which are essential in the development of new pharmaceuticals. Its role in creating specific peptide sequences allows for the exploration of potential therapeutic agents and drug candidates.
Used in Protein Structure and Function Studies:
In the study of protein structure and function, BOC-PRO-GLY-OH is used as a reference compound. Its well-defined structure and properties make it a valuable tool for understanding the behavior of amino acids within peptides and proteins, contributing to the advancement of protein science.
Used in Organic Chemistry Research:
BOC-PRO-GLY-OH is utilized in organic chemistry research as a model compound for studying peptide synthesis and the effects of protecting groups on reaction outcomes. This helps researchers optimize synthetic routes and develop new methodologies for peptide chemistry.

Upstream product

• 57294-31-2 Boc-Pro-Gly-OEt 
• 15761-39-4 N-tert-butoxycarbonyl-proline 
• 4530-20-5 BOC-glycine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 34290-72-7 tert-butyloxycarbonyl-prolyl-glycine methyl ester 
• 31953-80-7 N-tert-butyloxycarbonyl-(2S)-prolyl-glycine benzyl ester 
• 3392-10-7 Pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(2,5-dioxo-pyrrolidin-1-yl) ester 
• 56-40-6 glycine 
• 109-02-4 4-methyl-morpholine 
• 1738-76-7 glycine benzyl ester p-toluenesulfonic acid salt 
• 543-27-1 isobutyl chloroformate 
• 147-85-3 L-proline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 57294-31-2 tert-butyl (S)-2-((2-ethoxy-2-oxoethyl)carbamoyl)pyrrolidine-1-carboxylate 

Downstream Products

• 407629-42-9 t-BuOCO-L-Pro-Gly-Gly-Gly-OCH₂Ph₂ 
• 92837-95-1 Boc-Pro-Gly-Cys(SBz)-NHMe 
• 2578-57-6 N-prolylglycine 
• 261724-05-4 C₃₈H₅₀N₆O₁₀ 
• 261724-09-8 3,5-Bis-[2-({(S)-1-[2-((2R,3S,4R,5S,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yl)-acetyl]-pyrrolidine-2-carbonyl}-amino)-acetylamino]-benzoic acid 
• 261724-08-7 3,5-Bis-[2-({(S)-1-[2-((2R,3S,4R,5S,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yl)-acetyl]-pyrrolidine-2-carbonyl}-amino)-acetylamino]-benzoic acid benzyl ester 
• 72122-62-4 L-tyrosyl-L-prolyl-L-phenylalanyl-L-prolyl-glycyl-L-prolyl-L-isoleucine 
• 85713-96-8 N-tert-butyloxycarbonyl-L-prolyl-L-phenylalanyl-L-prolylglycine 
• 47283-59-0 L-phenylalanyl-L-prolylglycine 
• 82289-41-6 des-Tyr¹-β-casomorphin-5 
• 77654-52-5 L-prolyl-L-phenylalanyl-L-prolylglycyl-L-prolyl-L-isoleucine 
• 66211-31-2 N-tert-butyloxycarbonyl-L-phenylalanyl-L-prolylglycine 
• 85642-28-0 tert-butyl N-tert-butyloxycarbonyl-L-prolyl-L-phenylalanyl-L-prolylglycyl-L-prolyl-L-isoleucinate 
• 85642-26-8 N-tert-butyloxycarbonyl-L-tyrosyl-L-prolyl-L-phenylalanyl-L-prolylglycyl-L-prolyl-L-isoleucine 

Relevant academic research and scientific papers

Leonurine derivative and application thereof in preparing medicine for preventing or treating ischemic cerebrovascular diseases

The invention provides a leonurine derivative and application of the leonurine derivative in preparation of a medicine for preventing or treating ischemic cerebrovascular diseases. The leonurine derivative has a structure as shown in a general formula (I), wherein X is selected from O or NH; Y is selected from any one of natural amino acid, substituted amino acid or amino alcohol; Z is selected from H, proline and any substituted proline. Pharmacological experiments prove that the leonurine derivative provided by the invention has the effects of neuroprotection, cerebral infarction area reduction and animal neurobehavioral scoring, and is good in safety, so that the leonurine derivative has important significance for developing novel medicines for preventing or treating ischemic cerebrovascular diseases.

Design, synthesis, and biological evaluation of novel stachydrine derivatives as potent neuroprotective agents for cerebral ischemic stroke

Stachydrine is a natural product with multiple protective biological activities, including those involved in preventing cancer, ischemia, and cardiovascular disease. However, its use has been limited by low bioavailability and unsatisfactory efficacy. To address this problem, a series of stachydrine derivatives (A1/A2/A3/A4/B1/B2/B3/B4) were designed and synthesized, and biological studies were carried out in vitro and in vivo. When compared with stachydrine, Compound B1 exhibited better neuroprotective effects in vitro, and significantly reduced infarction size in the model of the middle cerebral artery occlusion rat model. Therefore, Compound B1 was selected for further research on ischemic stroke. [Figure not available: see fulltext.].

METHOD FOR PRODUCING RECOMBINANT PEPTIDE AND RESULTANT PEPTIDE

PROBLEM TO BE SOLVED: To provide peptides with reproductive- and sexual-function stimulating activity. SOLUTION: The peptides are represented by general formula: A-Thr-Lys-Pro-B-C-D-X (where A is 0, Met, Met(O), Thr, Ala, His, Phe, Lys, or Gly; B is 0, Gly, Asp, Trp, Gln, Asn, Tyr, Pro, or Arg; C is 0, Arg, Phe, Tyr, Gly, His, Pro, or Lys; D is 0, Val, Gly, Tyr, Trp, Phe, or His; and X is OH, OCH3, or NH2; where 0 represents absence of the amino acid residue; provided that if A≠0 then B ≠0 and/or C≠0 and/or D≠0, if B≠0 then C≠0 and/or D≠0, and peptides Phe-Thr-Lys-Pro-Gly, Thr-Lys-Pro-Pro-Arg and Thr-Lys-Pro-Arg-Gly are excluded). SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2020,JPO&INPIT

PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME

Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.

Synthesis of cytotoxic cyanobactin, Wewakazole B

We report herein the synthesis of cytotoxic cyanobactin, Wewakazole B through an efficient solution-phase approach. The key steps of the synthesis are the macrocyclic lactamization of linear dodecapeptide and construction of two hexapeptides with three di

Aggregation propensity of amyloidogenic and elastomeric dipeptides constituents

This study demonstrates the self-assembly of N- and C-terminal protected dipeptides Phe–Gly and Pro–Gly which were derived from amyloidogenic and elastomeric peptide sequences. These constituents afforded nanostructured supramolecular ensembles through va

Stability of His-Phe-Arg-Trp-Pro-Gly-Pro to Leucine Aminopeptidase, Carboxypeptidase Y, and Rat Nasal Mucus, Blood, and Plasma

The His-Phe-Arg-Trp-Pro-Gly-Pro [ACTH-(6-9)-PGP] peptide was synthesized. Proteolysis of ACTH-(6-9)-PGP and semax (Met-Glu-His-Phe-Pro-Gly-Pro) in the presence of leucine aminopeptidase and carboxypeptidase Y was studied. If the proteolysis of ACTH-(6-9)-PGP is mainly defined by aminopeptidases, the basic metabolite is Trp-Pro-Gly-Pro. Identification of major metabolites of ACTH-(6-9)PGP when incubated with the enzymes in vitro made it possible to evaluate proteolysis pathways of the peptide and prepare necessary amounts of its metabolites for using them as standards. Kinetics of ACTH-(6-9)PGP degradation in the presence of enzyme systems of nasal mucus, blood, and plasma were also explored. It was found that proteolysis of ACTH-(6-9)-PGP in rat blood and plasma occurs mainly under the effect of enzymes whose action is similar to leucine aminopeptidase.

Method for producing a recombinant peptide and resultant peptide

The invention relates to peptides with the following general formula: [in-line-formulae]A-Thr-Lys-Pro-B-C-D-X, where:[/in-line-formulae] A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly B—0, Gly, Asp, Trp, Gln, Asn, Tyr, Pro, Arg C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys D—0, Val, Gly, Tyr, Trp, Phe, His X—OH, OCH3, NH2, where 0 is no amino acid residue, provided that if A≠0, then B and/or C and/or D≠0, if B≠0, then C and/or D≠0, excluding the peptides Phe-Thr-Lys-Pro-Gly (SEQ ID NO: 1), Thr-Lys-Pro-Pro-Arg (SEQ ID NO: 2), Thr-Lys-Pro-Arg-Gly (SEQ ID NO: 3).

Synthesis, docking and anticancer activity studies of D-proline- incorporated wainunuamide

D-proline-incorporated wainunuamide - a cyclic octapeptide was synthesized and characterized by FTIR, 1H and 13C NMR and Mass spectral analysis. Molecular docking studies were carried out for the designed cyclic octapeptide and the results showed greater affinity for HPV18-2IOI receptor (HeLa cancer cell line). The synthesized cyclic octapeptide exhibited potent anticancer activity against HeLa cancer cells. Indian Academy of Sciences.

Structural-functional study of glycine-and-proline-containing peptides (Glyprolines) as potential neuroprotectors

A synthetic scheme for preparation of (Gly-Pro) n, (Pro-Gly) n (n = 2, 3), and (Pro-Gly-Pro) n (n = 1, 2) peptides was elaborated. The effect of the synthesized peptides and the Gly-Pro and Pro-Gly dipeptides on survival of cultured cells of PC12 rat pheochromocytoma was studied under the conditions of oxidative stress induced by brief incubation of the cells with hydrogen peroxide. Peptides of the general formula (Gly-Pro) n and the Pro-Gly-Pro peptide at a concentration of 0.2-100 μM were shown to decrease the number of damaged cells. The Gly-Pro peptide was the most active and decreased the number of damaged cells by 49% on average at a concentration of 100 μM.